Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

s and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-nave group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

The treatment regimen was generally well-tolerated, as only non-severe side effects were observed, including diarrhea, fatigue, chest infection, rash, nausea, joint pain, and infrequent and transient low blood counts. Investigators found no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients. These results demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL.

"As we learn more about how to target specific essential survival signa
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... 2014 Senior Planning Services, providing “expert ... nonprofit organization providing the adult demographic education and ... seniors navigate the rough seas of applying for Medicaid. ... on the topic of Medicaid eligibility and proper planning, ... of applying for this coverage. , Senior Planning ...
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... 26, 2014 Louisiana Back Institute, ... specialists in minimally invasive spine surgery, announces today ... the rapidly growing provider network of orthopedic spine ... coincides with the network’s continuing success providing the ... Louisiana residents who are suffering from orthopedic spine ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... with endometriosis may one day lead to new ways ... research suggests. What's more, the researchers may have also ... consequence of the condition. ,Anywhere from 10 to 15 ... when the tissue //that lines the uterus, the endometrium, ...
... take the newer, lower-dose birth control pills are not increasing ... birth control pills debuted in the 1960s, doctors have worried ... studies looking at the link, however, have looked at women ... levels of estrogen compared to those in use today. Whether ...
... may have solved the mystery of why dengue fever, unlike ... Dengue is a debilitating, sometimes fatal illness endemic to much ... by high fever, bone and muscle pain and -- in ... ,Dengue is also unusual in that //symptoms are more severe ...
... aren’t beneficial in the prevention of heart disease or ... speculated antioxidant vitamins, such as beta carotene (a form ... role in helping people avoid cardiovascular disease. The vitamins ... of dangerous plaque. Several preclinical studies show supplementing //the ...
... experienced a significant reduction in blood pressure as ... according to a new study. ,To investigate the ... the rest-activity cycle, Ramon C. Hermida, Ph.D., of ... Universitario, Spain, and colleagues studied a group of ...
... high cholesterol levels are more likely to develop high ... eating habits and cholesterol levels of nearly 450 preschool ... by doctors and had their HDL, or good cholesterol, ... the study show children with the highest levels of ...
Cached Medicine News:Health News:Scientists crack dengue fever puzzle 2Health News:Night Time Aspirin Regimen Found to Reduce Blood Pressure 2
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... Nov. 25, 2014  Array BioPharma Inc. ... that its Chief Executive Officer, Ron ... upcoming conferences.  The public is welcome to ... the Array BioPharma website:  www.arraybiopharma.com .Event: Piper ... p.m.  Eastern Time Location: Palace Hotel, New ...
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... , June 4 Amgen executive Alan ... of BeneChill, a privately held medical device company launching its ... response teams in the field, later this year in ... the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger ...
... BURLINGTON, Vt ., June 4 Mach 7 ... solutions, has relocated its global headquarters from suburban Chicago ... as the company,s base for Americas, sales and professional service operations, ... management and strategic R&D functions. , ...
Cached Medicine Technology:Veteran International Health Care Executive Appointed CEO of BeneChill(R) 2Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Uvex Patriot Frame...
... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...
... Radiation Protection Goggles ... can be used by ... mm leaded glass, 1.0 ... shields provide increased scatter ...
Medicine Products: